



MATTHEW J. ROBSON, Ph.D.

MSB 3202

231 Albert Sabin Way

Cincinnati, OH 45267

Tel: (513) 558-0333

Email: Matthew.Robson@UC.edu

EDUCATION

West Virginia University 2008 - 2013
Doctor of Philosophy – Pharmaceutical and Pharmacological Sciences
Graduate Advisor: Rae R. Matsumoto, Ph.D.

Canisius College 2003 - 2007
Bachelor of Science – Biochemistry

RESEARCH EXPERIENCE

University of Cincinnati – Division of Pharmaceutical Sciences
James L. Winkle College of Pharmacy 2018 - Present
Assistant Professor

Florida Atlantic University – Department of Biomedical Sciences
Charles E. Schmidt College of Medicine - Jupiter, FL 2016 - 2018
Research Assistant Professor

Vanderbilt University – Department of Pharmacology
School of Medicine - Nashville, TN 2013 - 2016
Research Fellow
Postdoctoral Advisor: Randy D. Blakely, Ph.D.

West Virginia University – Department of Pharmaceutical and Pharmacological Sciences
School of Pharmacy - Morgantown, WV 2008 - 2013
Graduate Research Assistant

Sub-Investigator Glaxo-Smith Kline Clinical Trial - Buffalo, NY 2008 - 2009
Dent Neurologic Institute Study Site

Dent Neurologic Institute – Buffalo, NY 2005 - 2008
Research Associate – Division of Neuropharmacology

PEER REVIEWED PUBLICATIONS

Gengo FM, Rubin L, **Robson M**, Gengo MF, Mager DE, Rainka MR, Bates VE. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. **Journal of Clinical Pharmacology**. 2008. **48**(1): 117-122. PubMed ID: 18094224

Gengo FM, Rainka MR, **Robson M**, Gengo MF, Forrest A, Hourihane M, Bates VE. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. **Journal of Clinical Pharmacology**. 2008. **48**(3): 335-343. PubMed ID: 18223144

Fishback JA, **Robson MJ**, Xu Y, Matsumoto RR. Sigma receptors: potential targets for a new class of antidepressant drug. **Pharmacology and Therapeutics**. 2010. **127**(3): 271-282. PubMed ID: 20438757

Kaushal N, **Robson MJ**, Vinnakota H, Narayanan S, Avery BA, McCurdy CR, Matsumoto RR. Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. **AAPS Journal**. 2011. **13**(3): 336-346. PubMed ID: 21494909

Mesangeau C, Amata E, Alsharif W, Seminerio MJ, **Robson MJ**, Matsumoto RR, Poupaert JH, McCurdy CR. Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. **European Journal of Medicinal Chemistry**. 2011. **46**(10): 5154-5161. PubMed ID: 21899931

Robson MJ, Elliott M, Seminerio MJ, Matsumoto RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. **European Neuropsychopharmacology**. 2012. **22**(4): 308-317. PubMed ID: 21911285

Kaushal N, Elliott M, **Robson MJ**, Iyer AKV, Rojanasakul Y, Coop A, Matsumoto RR. AC927, a sigma ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. **Molecular Pharmacology**. 2012. **81**(3): 299-308. PubMed ID: 22101517

Seminerio MJ, **Robson MJ**, Abdelazeem AH, Mesangeau C, Jamalapuram S, Avery BA, McCurdy CR, Matsumoto RR. Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. **AAPS Journal**. 2012. **14**(1): 43-51. PubMed ID: 22183188

Xu YT, **Robson MJ**, Szeszel-Fedorowicz W, Patel D, Rooney R, McCurdy CR, Matsumoto RR. CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. **Pharmacology Biochemistry & Behavior**. 2012. **101**(1): 174-180. PubMed ID: 22234290

Robson MJ, Noorbakhsh B, Seminerio MJ, Matsumoto RR. Sigma-1 receptors: potential targets for the treatment of substance abuse. **Current Pharmaceutical Design**. 2012. **18**: 902-919. PubMed ID: 22288407

Seminerio MJ, **Robson MJ**, McCurdy CR, Matsumoto RR. Sigma receptor ligands attenuate methamphetamine-induced hyperthermia by a mechanism independent of IL-1 β mRNA expression in the hypothalamus. **European Journal of Pharmacology**. 2012. **691**(1-3): 103-109. PubMed ID: 22820108

Kaushal N, Seminerio MJ, **Robson MJ**, McCurdy CR, Matsumoto RR. Pharmacological evaluation of SN79, a sigma receptor ligand against methamphetamine-induced neurotoxicity in vivo. **European Neuropsychopharmacology**. 2012. **23**: 960-971. PubMed ID: 22921523

Turner RC, Lucke-Wold B, **Robson MJ**, Omalu BI, Petraglia AL, Bales JE. Repetitive traumatic brain injury and development of chronic traumatic encephalopathy: a potential role for biomarkers in diagnosis, prognosis and treatment? **Frontiers in Neurology**. 2013. **3**: 186. PubMed ID: 23335911

Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR. Sigma receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. **Pharmacological Reports**. 2013. **65**(2): 343-349. PubMed ID: 23744418

Robson MJ, Turner RC, Naser ZJ, McCurdy CR, Huber JD, Matsumoto RR. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. **Experimental Neurology**. 2013. **247**: 134-142. PubMed ID: 23631864

Turner RC, Naser ZJ, Logsdon AF, DiPasquale K, Jackson GJ, **Robson MJ**, Gettens RTT, Matsumoto RR, Rosen CL, Huber JD. Modeling clinically relevant blast parameters based on scaling principles produces functional and histological deficits in rats. **Experimental Neurology**. 2013. **248**: 520-529. PubMed ID: 23876514

Matsumoto RR, Nguyen L, Kaushal N, **Robson MJ**. Sigma (σ) receptors as potential therapeutic targets to mitigate psychostimulant effects. **Advances in Pharmacology**. 2014. **69**(9): 323-386. PubMed ID: 24484982

Kaushal N, **Robson MJ**, Rosen A, McCurdy CR, Matsumoto RR. Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[*d*]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro. **European Journal of Pharmacology**. 2014. **724**: 193-203. PubMed ID: 24380829

Robson MJ, Turner RC, Naser ZJ, Huber JD, McCurdy CR, Matsumoto RR. SN79, a sigma receptor ligand, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation. **Experimental Neurology**. 2014. **254**: 180-189. PubMed ID: 24508558

Nguyen L, **Robson MJ**, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. **PLOS One**. 2014. **9**(2): e89985. PubMedID: 24587167

Matsumoto RR, Seminerio MJ, Turner RC, **Robson MJ**, O'Callaghan JP, Miller DB. Methamphetamine-induced hyperthermia: a comprehensive review. **Pharmacology and Therapeutics**. 2014. **144**(1): 28-40. PubMedID: 24836729

Nguyen L, Kaushal N, **Robson MJ**, Matsumoto RR. Sigma receptors as potential therapeutic targets for neuroprotection. **European Journal of Pharmacology**. 2014. **743**: 42-47. PubMed ID: 25261035

Logsdon AF, Turner RC, Lucke-Wold BP, **Robson MJ**, Naser ZJ, Smith KE, Matsumoto RR, Huber JD, Rosen CE. Altering endoplasmic reticulum stress in a model of blast-induced traumatic brain injury controls cellular fate and ameliorates neuropsychiatric symptoms. **Frontiers in Cellular Neuroscience**. 2014. **8**: 421. PubMed ID: 25540611

Nguyen L, Lucke-Wold BP, Mookerjee SA, Cavendish JZ, **Robson MJ**, Scandinaro AL, Matsumoto RR. Role of sigma-1 receptors in neurodegenerative diseases. **Journal of Pharmacological Sciences**. 2015. **127**(1): 17-29. PubMed ID: 25704014

Turner RC, Lucke-Wold BP, Logsdon AF, **Robson MJ**, Dashnaw M, Huang JH, Smith KE, Huber J, Rosen C, Petraglia A. The quest to model chronic traumatic encephalopathy: a multiple model and injury paradigm experience. **Frontiers in Neurology**. 2015. **6**(222). PubMed ID: 26539159

Baganz NL, Lindler KM, Zhu CB, Smith JT, **Robson MJ**, Iwamoto H, Deneris ES, Hewlett WA, Blakely RD. A requirement of serotonergic p38 α mitogen activated protein kinase for peripheral immune system activation of serotonin uptake and serotonin linked behaviors. **Translational Psychiatry**. 2015. **5**(e671). PubMed ID: 26529424

Lucke-Wold BP, Naser ZJ, Logsdon AF, Turner RC, Smith KE, **Robson MJ**, Bailes JE, Lee JM, Rosen CL, Huber JD. Amelioration of nicotinamide adenine dinucleotide phosphate-mediated stress reduces cell death after blast-induced traumatic brain injury. **Translational Research**. 2015. **6**: 509-528 PubMed ID: 26414010

Turner RC, Lucke-Wold BP, Logsdon AF, **Robson MJ**, Lee J, Bailes J, Dashnaw M, Huber J, Petraglia A, Rosen C. Modeling chronic traumatic encephalopathy: the way forward for future discovery. **Frontiers in Neurology**. 2015. **6**(223). PubMed ID: 26579067

Lucke-Wold BP, Turner RC, Logsdon AF, Nguyen L, Bailes JE, Lee JM, **Robson MJ**, Omalu BI, Huber JD, Rosen CL. Endoplasmic reticulum stress implicated in chronic traumatic encephalopathy. **Journal of Neurosurgery**. 2016. **124**(3): 687-702. PubMed ID: 26381255

Gengo FM, Rainka M, Westphal E, Janda M, **Robson MJ**, Hourihane M, Bates V. Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg. **Journal of Clinical Pharmacology**. 2016. **56**(4): 414-421. PubMed ID: 26239393

Robson MJ, Zhu CB, Quinlan MA, Botschner DA, Baganz NL, Lindler KM, Thome JG, Hewlett WA, Blakely RD. Generation and characterization of mice expressing a conditional allele of the interleukin-1 receptor type 1. **PLOS One**. 2016. DOI: 10.1371/journal.pone.0150068. PubMed ID: 26930558

Turner RC, Lucke-Wold BP, **Robson MJ**, Lee JM, Bailes JE. Alzheimer's disease and chronic traumatic encephalopathy: Distinct but possibly overlapping disease entities. **Brain Injury**. 2016. **11**: 1-14. PubMed ID: 27715315

Robson MJ, Quinlan MA, Blakely RD. Immune system activation and depression: roles of serotonin in the central nervous system and periphery. **ACS Chemical Neuroscience**. 2017. **8**(5): 932-942. PubMed ID: 28345868

Burke SJ, Batdorf HM, Burk DH, Martin TM, Mendoza T, Stadler K, Alami W, Karlstad MD, **Robson MJ**, Blakely RD, Collier JJ. Pancreatic deletion of interleukin-1 receptor disrupts whole body glucose homeostasis and promotes islet β -cell de-differentiation. **Molecular Metabolism**. 2018. **18**: S2212-8778. PubMed ID: 29914854

Robson MJ, Quinlan MA, Margolis KG, Gajewski-Kurdziel PA, Veenstra-Vanderweele J, Gershon MD, Watterson MD, Blakely RD. p38 α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. **PNAS**. 2018. **115**(43): E10245-E10254

Liu X, Nemeth DP, McKim DB, Zhu L, DiSabato DJ, Berdysz O, Gorantla G, Oliver B, Witcher KG, Wang Y, Negray CE, Sheridan JF, Godbout JP, **Robson MJ**, Blakely RD, Popovich PG, Bilbo SD, Quan N. Cell-type-specific interleukin-1 receptor 1 signaling in the brain regulates distinct neuroimmune activities. **Immunity**. 2019. **50**: 1-17.

- Quinlan MA, Krout D, Katmaish RM, **Robson MJ**, Nettesheim C, Gresch PJ, Mash DC, Henry K, Blakely RD. Human serotonin transporter coding variation establishes conformational bias with functional consequences. **ACS Chemical Neuroscience**. 2019. **10**(7): 3249-3260. PubMed ID: 30668912
- Khalid F, Yang GL, McGuire JL, **Robson MJ**, Foreman B, Ngwenya LB, Lorenz JN. Autonomic dysfunction following traumatic brain injury: translational insights. **Journal of Neurosurgery**. 2019. **47**(5): E8. PubMed ID: 31675718
- Thome J, Reeder E, Collins S, Gopalan P, **Robson MJ**. Contributions of interleukin-1 receptor signaling in traumatic brain injury. **Frontiers in Behavioral Neuroscience**. 2020. **113**: 287. PubMed ID: 32038189
*Editors Manuscript Pick for 2021
- Quinlan MA, **Robson MJ**, Ye R, Rose K, Schey KL, Blakely RD. Ex vivo quantitative proteomic analysis of serotonin transporter interactome: network impact of the SERT ala56 coding variant. **Frontiers in Molecular Neuroscience**. 2020. **13**: 89. PubMed ID: 32581705
- Sturchio A, Marsili L, Vizcarra JA, Dwivedi AK, Kauffman MA, Duker AP, Lu P, Pauciulo MW, Wissel BD, Hill EJ, Stecher B, Keeling EG, Vagal AS, Wang L, Haslam DB, **Robson MJ**, Tanner CM, Hagey DW, Andaloussi SE, Ezzat K, Fleming RMT, Lu LJ, Little MA, Espay AJ. Phenotype-agnostic molecular subtyping of neurodegenerative disorders: the Cincinnati Cohort Biomarker Program (CCBP). **Frontiers in Aging Neuroscience**. 2020. **12**: 553635. PubMed ID: 33132895
- Logsdon AF, Lucke-Wold BP, Turner RC, Collins SM, Reeder EL, Huber JD, Rosen CL, **Robson MJ**,* Plattner F.* Compression wave injury model for preclinical assessment of closed-head mild traumatic brain injury in rodents. **Journal of Visualized Experiments**. 2020. **165**. PubMed ID: 33226021
*Co-Corresponding Author
- Ren J, Lu X, Hall G, Privratsky JR, Robson MJ, Blakely RD, Crowley SD. IL-1 receptor signaling in podocytes limits susceptibility to glomerular damage. **American Journal of Physiology – Renal Physiology**. 2022. **322**: 164-174. PubMed ID: 34894725
- Collins SM, O’Connell CJ, Reeder EL, Norman S, Lungani K, Gopalan P, Gudelsky GA, **Robson MJ**. Altered serotonin 2A (5-HT_{2A}) receptor signaling underlies mild TBI-elicited deficits in social dominance. **Frontiers in Pharmacology**. 2022. **13**. PubMed ID: 35910378
- O’Connell CJ, Reeder EL, Collins SM, Lungani K, Norman SV, **Robson MJ**. Mild traumatic brain injury elicits time- and region specific reductions in serotonin transporter protein expression and uptake capacity. **NeuroReport**. 2022. **33**(14): 612-616. PubMed ID: 36062511
- Reeder EL, Liber M-L, Traubert OD, O’Connell CJ, Turner RC, **Robson MJ**. Characterization of blast waveforms produced by different driver gasses in an open-ended shock tube model. **arXiv**. 2022. Preprint. Online.
- Reeder EL, Liber M-L, Traubert OD, O’Connell CJ, Turner RC, **Robson MJ**. Effect of driver gas composition of production of scaled Friedlander waveforms in an open-ended shock tube model. **Biomedical Physics & Engineering Express**. 2022. **8**(6): 065028. PubMed ID: 36252558
- Reeder EL, O’Connell CJ, Collins SM, Traubert OD, Norman S, Caceres RA, Sah R, Smith DW, **Robson MJ**. Increased carbon dioxide respiration prevents the effects of acceleration/deceleration elicited mild traumatic brain injury. **Neuroscience**. 2023. **509**: 20-35. PubMed ID: 36332692

Singer KE, McGlone ED, Collins SM, Wallen TE, Morris MC, Schuster R, England L, Stevens-Topie S, **Robson MJ**, Goodman MD. Propranolol reduces p-tau accumulation and improves behavioral outcomes in a polytrauma murine model. **Journal of Surgical Research**. 2023. 282: 183-190. PubMed ID: 36308901

Hetzer SM, O'Connell CJ, Lallo V, **Robson MJ**, Evanson NK. Model matters: Differential outcomes in traumatic optic neuropathy pathophysiology between blunt and blast-wave mediated head injuries. **bioRxiv**. 2023. DOI: <https://doi.org/10.1101/2023.05.25.542261>

ABSTRACTS

Gengo FM, Rainka M, Rubin L, Gengo M, **Robson MJ**, Bates V. Effects on the magnitude and time course of aspirin-induced inhibition of platelet aggregation by ibuprofen and the clinical consequences in secondary stroke prophylaxis. **Journal of Clinical Pharmacology**. 2006. 46(9): 1073.

Gengo FM, **Robson MJ**, Gengo MF, Rainka MR, Hourihane M, Bates VE. The prevalence of platelet non-responsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. **Stroke**. 2006. 37(2): 715.

Gengo FM, Liana D, **Robson MJ**, Gengo M, Rainka M, Bates V. Effect of ascorbic acid on platelet responsiveness to clopidogrel in patients treated for secondary stroke prophylaxis. **Stroke**. 2008. 39: 624.

Gengo FM, Rainka M, Westphal E, **Robson MJ**, Gengo M, Hourihane M, Bates V. Platelet response to increased aspirin dose in patients whose platelets were non-responsive to lower aspirin doses. **Stroke**. 2009. 40(4): 22-23.

Gengo FM, Iyer V, **Robson MJ**, Gengo M, Rainka M, Forrest A. Effects of naproxen on the time course of aspirin-induced inhibition of platelet aggregation. **Clinical Pharmacology and Therapeutics**. 2009. 85(Suppl. 1): S40.

Robson MJ, Shaikh J, Elliott M, Xu YT, Healy JR, Matsumoto RR. The antidepressant-like actions of ketamine in vivo and in vitro: role of sigma receptors. **Journal of Clinical Pharmacology**. 2010. 50(9): 1084.

Gengo FM, Rainka M, Westphal E, Radecki L, **Robson MJ**, Hourihane M, Bates V. An assay to assess antiplatelet effects of dipyridamole at therapeutic concentrations. **Journal of Clinical Pharmacology**. 2010. 50(9): 1069.

Gengo FM, **Robson MJ**, Rainka M, Westphal E, Gengo M, Hourihane M, Bates V. The prevalence of platelet non-responsiveness to clopidogrel and the effect of cytochrome P450 1A2 inducing medications. **Journal of Clinical Pharmacology**. 2010. 50(9): 1069.

Robson MJ, Chen D, Szeszel-Fedorowicz W, Matsumoto RR. Sigma receptor antagonists attenuate methamphetamine-induced genetic alterations in the striatum. Program No. 896.03. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

Seminario MJ, **Robson MJ**, Abdelazeem AH, Mesangeau C, McCurdy CR, Matsumoto RR. The evaluation of an optimized sigma receptor ligand on methamphetamine-induced dopaminergic neurotoxicity and hyperthermia. Program No. 896.01. 2011 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2011. Online.

Wollenberg L, Iyer V, **Robson MJ**, Gengo M, Gengo FM, Rainka M, Forrest A, Mager D. Application of a mechanism-based, population pharmacodynamic model of the time-course of platelet aggregation when naproxen and aspirin are administered alone and in combination. **Pharmacotherapy**. 2012. **32**(5): e115.

Seminario MJ, **Robson MJ**, Mesangeau C, Narayanan S, McCurdy CR, Matsumoto RR. Sigma receptor ligands attenuate methamphetamine-induced hyperthermia but do not modulate IL-1 β mRNA expression in select brain regions. **FASEB J**. 2012. **26**(Meeting Abstract Supplement): 1043.2

Robson MJ, McCurdy CR, Matsumoto RR. Methamphetamine elicits PERK-mediated endoplasmic reticulum stress transcriptional responses in NG108-15 cells. Program No. 360.12. 2012 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2012. Online.

Robson MJ, Turner RC, Naser ZJ, Huber JD, McCurdy CR, Matsumoto RR. SN79, a sigma receptor ligand, mitigates methamphetamine-induced astrocyte and microglial activation. **FASEB J**. 2013. **27**(Meeting Abstract Supplement): 1175.2

Matsumoto RR, Kaushal N, **Robson MJ**, McCurdy CR, Coop A. Attenuation of methamphetamine-induced neurotoxicity by selective sigma receptor ligands: in vivo and in vitro studies. **FASEB J**. 2013. **27**(Meeting Abstract Supplement): 659.13

Matsumoto RR, **Robson MJ**, McCurdy CR, Coop A, Kaushal N. Attenuation of methamphetamine-induced neurotoxicity by selective sigma receptor ligands: Involvement of neuronal and glial mechanisms. Program No. 213.07. 2013 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2013. Online.

Nguyen L, **Robson MJ**, Matsumoto RR. Dextromethorphan produces antidepressant-like effects in mice. Program No. 503.10. 2013 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2013. Online.

Robson MJ, Zhu CB, Lindler KM, Baganz N, Wright J, Hewlett W, Blakely RD. Conditional elimination of the interleukin-1 receptor for the study of the impact of inflammatory cytokines on brain and behavior. **Neuropsychopharmacology**. 2013. **38**(Meeting Abstract Supplement): S115-S116

Robson MJ, Zhu CB, Lindler KM, Baganz N, Wright J, Hewlett W, Blakely RD. Conditional elimination of the interleukin-1 receptor: connecting CNS immune signaling, serotonin transporter modulation and depressive behavior. **Basic and Clinical Pharmacology and Toxicology**. 2014. **115**(Supplement 1): 288.

Westphal E, Gengo F, Rainka M, **Robson M**, Hourihane M, Bates V. Platelet response to increased aspirin dose in patients whose platelets were non-responsive to lower aspirin doses. **Neurology**. 2014. **82**. P1. 108

Matsumoto RR, **Robson MJ**, Kaushal N, Coop A. Selective sigma receptor ligands attenuate methamphetamine-induced neurotoxicity and genetic alterations in the striatum: microarray study and validation of select targets. Program No. 227.20. 2014 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2014. Online.

Robson MJ, Watterson DM, Veenstra-Vanderweele J, Poch AM, Blakely RD. Pharmacological reversal of autism spectrum disorder social deficits in the SERT Ala56 mouse via p38 MAPK α blockade. Program No. 519.17. 2014 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2014. Online.

Baganz NL, Smith JT, Harbom LJ, **Robson MJ**, Blakely RD. Contributions of interleukin-1 β signaling to the enduring effects of early-life stress: A serotonin connection? Program No. 503.12. 2014 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2014. Online.

Baganz NL, Smith JT, Harbom LJ, **Robson MJ**, Hewlett W, Blakely RD. Contributions of inflammatory cytokine signaling to the enduring effects of early-life stress: A serotonin connection? **Neuropsychopharmacology**. 2014. **39**(Meeting Abstract Supplement): S326-S327

Robson MJ, Watterson DM, Veenstra-Vanderweele J, Blakely RD. Antagonism of p38 α MAPK signaling corrects receptor hypersensitivity and altered social behavior in the SERT Ala56 genetic mouse model of autism spectrum disorder. **Neuropsychopharmacology**. 2014. **39**(Meeting Abstract Supplement): S611-S612

Matsumoto RR, **Robson MJ**, Turner R, Naser Z, Kaushal N, McCurdy CM, Huber J, O'Callaghan J. Attenuation of methamphetamine-induced striatal neurotoxicity involves both neuronal and glial mechanisms. **Drug and Alcohol Dependence**. 2015. **146**: e197

Lucke-Wold B, **Robson MJ**, Logsdon AF, Turner RC, Rosen C. Reducing NADPH oxidative stress following acute neurotrauma. **FASEB J**. 2015. **29**(Meeting Abstract Supplement): LB497

Lucke-Wold BP, Turner RC, Rosen C, Naser Z, Logsdon A, Smith K, Huber J, **Robson M**, Bailes J, Lee J. Amelioration of NADPH-mediated stress reduces cell death following blast-induced traumatic brain injury. **Journal of Investigative Medicine**. 2015. **63**(4): 659-660

Baganz NL, Lindler KL, Zhu CB, Smith JT, **Robson MJ**, Iwamoto H, Deneris E, Hewlett W, Blakely RD. Role for p38 α Mitogen Activated Kinase in Serotonin Transporter Regulation and Serotonin Linked Behaviors Following Immune System Activation. 2015 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2015. Online.

Vargas CDM, Mavity-Hudson JA, **Robson MJ**, Veenstra-Vander Weele J, Wallace MT, Blakely RD, Casagrande VA. Changes in cortical wiring in a mouse model of autism. 2015 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2015. Online.

Robson MJ, Quinlan MA, Veenstra Vander-Weele J, Watterson DM, Blakely RD. Chronic antagonism of p38 α MAPK mitigates serotonin receptor hypersensitivity and social behavior deficits in the SERT Ala56 genetic mouse model of autism spectrum disorder. 2015 International Society for Tryptophan Research. Grand Rapids, MI.

Robson MJ, Watterson DM, Veenstra Vander-Weele J, Blakely RD. Synaptic serotonin transporters and autism: Insights into pathophysiology and mechanism-based treatments from the SERT Ala56 mouse model. 25th Neuropharmacology Conference. 2015. Synaptopathy – From Biology to Therapy. Chicago, IL.

Robson MJ, Quinlan MA, Veenstra Vander-Weele J, Watterson DM, Blakely RD. Chronic antagonism of p38 α MAPK normalizes serotonin clearance, serotonin receptor hypersensitivity and social behavior deficits in a genetic murine model of autism spectrum disorder. **FASEB J**. 2016. **30**(Meeting Abstract Supplement): 707.9

Lucke-Wold B, Logsdon A, Turner R, **Robson M**, Lockman P, Rosen C. Targeting trauma-induced blood brain barrier disruption: an innovative approach for treating concussion. **FASEB J**. 2016. **30**(Meeting Abstract Supplement): 706.70

Quinlan MA, Ye R, **Robson MJ**, Han Q, Ramamoorthy S, Blakely RD. State-dependent protein interactions stabilize hyperactive confirmation of the serotonin transporter. Seattle, WA. **12th International Society for Serotonin Research Meeting**. 2016.

Robson MJ, Quinlan MA, Veenstra Vander-Weele J, Watterson DM, Blakely RD. Chronic inhibition of p38 α MAPK normalizes serotonin clearance, serotonin receptor hypersensitivity and social behavior deficits in the SERT Ala56 genetic model of autism spectrum disorder. Seattle, WA. **12th International Society for Serotonin Research Meeting**. 2016.

Watterson D, Roy SM, Schavocky J, Grum-Tokars V, Bachstetter A, Minasov G, **Robson MJ**, Anderson W, Blakely R, Van Eldik L, Pelletier J, Arancio O. A discovery platform for selective and efficacious CNS drug candidates with high safety potential: a stress protein kinase inhibitor case study for potential disease modification. 2016 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2016. Online.

Robson MJ, Quinlan MA, Veenstra Vander-Weele J, Watterson DM, Blakely RD. p38 α MAPK inhibitors as potential treatments for Autism Spectrum Disorder: insights from the SERT Ala56 genetic mouse model. **Neuropsychopharmacology**. 2016. **41**(Meeting Abstract Supplement): S215

Baganz N, Smith J, Harbom L, **Robson MJ**, Hewlett WA, Blakely RD. Immune to insults? Cytokine modulation of serotonin signaling as a determinant of the translation of early-life stress to adult anxiety and depression. **Neuropsychopharmacology**. 2016. **41**(Meeting Abstract Supplement): S152-S153

Quinlan MA, **Robson MJ**, Ye R, Han Q, Ramamoorthy S, Blakely RD. State-dependent protein interactions stabilize hyperactive confirmation of the serotonin transporter. **Keystone Conference: Omics Strategies to Study the Proteome**. 2016.

Robson MJ, Quinlan MA, Veenstra-VanderWeele J, Watterson DM, Blakely RD. Pharmacologic Inhibition and Genetic Elimination of p38 α MAPK Normalizes Serotonergic System Alterations and Social Behavior Deficits in the SERT Ala56 Mouse Model of Autism Spectrum Disorder. **FASEB J**. 2017. **31**(Meeting Abstract Supplement): 813.10

Robson MJ, Quinlan MA, Veenstra-VanderWeele J, Watterson DM, Blakely RD. Do Neuroinflammatory Pathways Contribute to Serotonergic Alterations in Autism? p38 α MAPK Signaling Drives Perturbed Serotonin Clearance, Receptor Hypersensitivity, and Social Behavior Deficits in the SERT Ala56 Mouse. **Brain, Behavior and Immunity**. 2017. **66**: e36

Quinlan MA, Krout D, **Robson MJ**, Henry LK, Blakely RD. Structural, biochemical and functional evidence of a biased confirmation of serotonin transporters imposed by an autism-associated mutation. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017. Online.

Baganz NL, **Robson MJ**, Owens WA, Daws LC, Blakely RD. Investigation of IL-1 β activation of serotonin transporter-mediated serotonin clearance in vivo. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017. Online.

Logsdon AF, Lucke-Wold BP, Thome JG, Turner RC, **Robson MJ**. Contributions of astrocytic IL-1R1 signaling in blast-induced traumatic brain injury. **Brain, Behavior and Immunity**. 2018.

Baganz NL, Smith JT, Harbom LJ, Castriz E, **Robson MJ**, Blakely RD. Contribution of inflammatory cytokine signaling to the enduring effects of early-life stress: A serotonin connection. **Brain, Behavior and Immunity**. 2018.

Liu X, Nemeth D, McKim D, Zhu L, DiSabato D, Berdysz O, Gorantla G, Oliver B, Witcher K, Wang Y, Sheridan J, Godbout J, **Robson M**, Blakely R, Popovich P, Bilbo S, Quan N. Structural and functional cytoarchitecture of IL-1R1-expressing system in the brain. **Brain, Behavior and Immunity**. 2018.

Quinlan, MA, Gajewski-Kurdziel PA, Paffenroth K, Harrison F, **Robson MJ**, Ramamoorthy S, Blakely RD. In vivo impact of the conformational regulatory SERT phosphorylation site Thr276. **International Society for Serotonin Research**. 2018.

Gajewski-Kurdziel PA, **Robson MJ**, Baganz NL, Liu X, Quan N, Blakely RD. Establishing the CNS Serotonergic Contribution to the Molecular, Physiological and Behavioral Actions of Inflammatory Cytokine IL-1 β . **International Society for Serotonin Research**. 2018.

Gajewski-Kurdziel PA, Potts E, **Robson MJ**, Baganz NL, Liu X, Quan N, Blakely RD. Elucidation of the role of serotonergic IL-1R signaling in the CNS. **Neuropsychopharmacology**. 2018. **43**(Meeting Abstract Supplement).

Reeder EL, Collins SM, Gopalan P, Horchar MJ, **Robson MJ**. Increased cortical interleukin-1 receptor signaling following blast-induced traumatic brain injury. **FASEB J**. 2019. **33** (Meeting Abstract Supplement): 500.15

Collins SM, Reeder EL, Lungani K, Hussain A, Gudelsky GA, **Robson MJ**. Altered CNS serotonin signaling and social deficits elicited by blast-induced traumatic brain injury. **FASEB J**. 2019. **33** (Meeting Abstract Supplement): 500.7

Collins SM, Reeder EL, Lungani K, Hussain A, Gudelsky GA, **Robson MJ**. Altered CNS serotonin signaling and aberrant social behaviors stemming from blast-induced traumatic brain injury. **J. Neurotrauma**. 2019.

Collins SM, Reeder EL, Lungani K, Hussain A, O'Connell C, Gudelsky GA, **Robson MJ**. Alterations in CNS 5-HT_{2A} signaling and the generation of aberrant social behavior following blast-induced traumatic brain injury. 2019 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2019. Online.

Gajewski-Kurdziel PA, Potts E, Tillman A, **Robson MJ**, Baganz NL, Liu X, Quan N, Blakely RD. Serotonergic IL-1Rs support CNS inflammatory cytokine production and neuronal activation. **Neuropsychopharmacology**. 2019. **44**(Meeting Abstract Supplement).

Benton A,* Collins SM, **Robson MJ**. Transient reductions in serotonin transporter expression and function elicited by blast-induced traumatic brain injury. **FASEB J**. 2020. **34** (Meeting Abstract Supplement).

* Undergraduate National Travel Award Recipient (ASPET), cancelled due to COVID-19

Collins SM,* Reeder EL, O'Connell CJ, Gudelsky GA, **Robson MJ**. Blast-induced traumatic brain injury elicits sociability deficits and aggressive behaviors coinciding with transient variations in CNS 5-HT levels and 5-HT_{2A} hypersensitivity. **FASEB J**. 2020. **34** (Meeting Abstract Supplement).

* Postdoctoral Best Abstract and Travel Award Recipient (ASPET), cancelled due to COVID-19

Reeder EL, Collins SM, Gopalan P, Norman S, O'Connell CJ, **Robson MJ**. IRAK4 Inhibition Attenuates Interleukin-1-Induced Astroglia: A Potential Therapeutic Target for Neurodegenerative Disorders? **FASEB J**. 2020. **34** (Meeting Abstract Supplement).

Reeder EL, O'Connell CJ, Norman S, Smith D, **Robson MJ**. Carbon Dioxide Inhalation Mitigates Functional Deficits Elicited by Blast-Induced Traumatic Brain Injury. **FASEB J**. 2021. **35** (Meeting Abstract Supplement).

Hartings JA, Ngwenya LB, Balu R, Smith D, Jandarov R, **Robson MJ**, Foreman B. Hypocapnia Worsens Secondary Damage in Patients with Severe Traumatic Brain Injury. **Military Health System Research Symposium (MHSRS)**. 2021. *Cancelled due to COVID-19 pandemic.

Robson MJ, Reeder EL, O'Connell CJ, Norman SV, Collins SM, Hartings JA, Smith DW. Carbon Dioxide Inhalation Mitigates Acute Functional Deficits and Alterations in Hippocampal Gene Transcription Elicited by Blast-Induced Traumatic Brain Injury. **Military Health System Research Symposium (MHSRS)**. 2021. *Cancelled due to COVID-19 pandemic.

Reeder EL, O'Connell CJ, Norman SV, Smith DW, **Robson MJ**. Carbon Dioxide Inhalation Mitigates Functional Deficits Elicited by Blast-Induced Traumatic Brain Injury. **Ohio Miami Valley Society for Neuroscience**. Online. 2021

O'Connell CJ, Reeder EL, Collins SM, Norman SV, Caceres RA, **Robson MJ**. Blast-Induced Traumatic Brain Injury Alters Indoleamine-2,3 Dioxygenase 1 Expression and 5-HT_{2A} Receptor Sensitivity. **Ohio Miami Valley Society for Neuroscience**. Online. 2021

O'Connell CJ, Reeder EL, Caceres RA, Collins SM, Chilton KQ, Gudelsky GA, **Robson MJ**. Closed Head Traumatic Brain Injury Drives Protracted Inflammation and Remodeling of Serotonergic Architecture in the Dorsal Raphe Nucleus. **FASEB J**. 2022. 36 (Meeting Abstract Supplement).

Reeder EL, O'Connell CJ, Collins SM, Traubert OD, Norman SV, Caceres RA, Sah R, Smith DW, **Robson MJ**. Exploiting the Biologic Ability of Carbon Dioxide to Manipulate Cerebral Blood Flow in Order to Prevent Mild Traumatic Brain Injury. **Kentucky Spinal Cord and Head Injury Research Trust Symposium**. Lexington, KY. 2022

O'Connell, CJ, Reeder EL, Collins SM, Traubert OD, Chilton KQ, Gudelsky GA, **Robson MJ**. Disrupted Corticotropin Releasing Hormone Signaling in Vglut3high Serotonergic Neurons Drives Aberrant Social Behaviors Following Mild Traumatic Brain Injury. **Kentucky Spinal Cord and Head Injury Research Trust Symposium**. Louisville Kentucky. 2022

Reeder EL, O'Connell CJ, Traubert OD, Smith DW, **Robson MJ**. Exploiting the Biologic Ability of Carbon Dioxide to Manipulate Cerebral Blood Flow in Order to Prevent Mild Traumatic Brain Injury. **J. Neurotrauma**. 2022.

Walsh AE, Katamish RM, Kurdziel PA, **Robson MJ**, O'Reilly KC, Veenstra-Vanderweele J, Quan N, Blakely RD. Expression of Hypermorphic SERT Gly56Ala Substitution in Mice Induces Tonic Innate Immune Activation in the CNS In Vivo. 2022 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2022. Online.

Gajewski-Kurdziel PA, Tillman AN, Iwamoto H, **Robson MJ**, Baganz NL, Quan N, Blakely RD. Serotonergic IL-1R1 Modulates Transporter and Neuronal Activity in a Sex-Dependent Manner in Response to Peripheral Inflammation. **Neuropsychopharmacology**. 2022. 47(Meeting Abstract Supplement).

Hetzer S, O'Connell C, **Robson MJ**, Evanson N. Different functional and histological outcomes in blunt head vs single or repeat blast injury. **Investigative Ophthalmology & Visual Science**. 63(7): 4129. 2022.

O'Connell C, Reeder E, Brown R, **Robson MJ**, Gardner J. Concomitant mild traumatic brain and burn injury elicits a unique gene expression profile within the brain. **American Society of Pharmacology and Experimental Therapeutics (ASPET)**. 2023. 37 (Meeting Abstract Supplement).

Gajewski-Kurdziel P, Iwamoto H, Tillman A, Baganz NL, **Robson MJ**, Quan N, Blakely RD. Peripheral inflammation limits 5-HT neuron signaling capacity via serotonergic IL-1R1 to reduce 5-HT neuron excitability and enhance 5-HT clearance. 2023 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2023. Online. (*Submitted*).

Robson MJ, O'Connell C, Reeder E, Hymore J, Brown R, Notorgiacomo G, Caceres R, Collins SM, Gudelsky G. Traumatic brain injury disrupts serotonergic networks and transcriptional regulation in a neuron subpopulation-specific manner. **J. Neurotrauma**. 2023.

PATENTS

Blakely RD, Veenstra-Vanderweele J, **Robson MJ**, Watterson DM. Compositions and Methods for Treating Autism Spectrum Disorders. Provisional Patent 62081002. Filed November 17th, 2014.

FINANCIAL SUPPORT

Targeting IL-1R1 Mediated Anemia in Complex Combat-Related Burns
Department of Defense
CDMRP – Military Burn Research Program
Role: Co-Investigator (PI: Gardner)
\$300K/yr
Effective: August 2022 - Present

Transcriptional Regulation within 5-HT Neurons Following Blast Injury
University of Cincinnati James L. Winkle College of Pharmacy
Research Innovation Grant Program
PI: Matthew J. Robson, Ph.D.
Effective: June 15th, 2020 – Present

IL-1R Dependent Transcriptional Regulation Post-TBI
University of Cincinnati CCTST Just-In-Time Award
PI: Matthew J. Robson, Ph.D.
Effective: August 25th, 2020 – March 31st, 2021

CO₂-Induced SLOSH Mitigation as a Strategy to Prevent Traumatic Brain Injury
University of Cincinnati Faculty Research Cost Support Award
PI: Matthew J. Robson, Ph.D.
Effective: April 1st, 2019 – March 31st, 2020

Role of Sigma-1 Receptors in Traumatic Brain Injury
PhRMA Foundation Pharmacology/Toxicology Research Starter Grant
PI: Matthew J. Robson, Ph.D.
Effective: March 1st, 2019 – February 29th, 2020

Regulation of SERT Activity by IL-1R Signaling in Serotonergic Neurons
NARSAD Young Investigator Grant
PI: Matthew J. Robson, Ph.D.
Effective: January 1st, 2017 – June 31st, 2019

p38 α MAPK Signaling: Novel Therapeutic Target for the Treatment of Autism Spectrum Disorder
Postdoctoral Fellowship
PhRMA Foundation Pharmacology/Toxicology Fellowship

PI: Matthew J. Robson, Ph.D.
Effective: July 1st, 2015 – May 1st, 2016

Training Program in Ion Channel and Transporter Biology
Postdoctoral Fellow
NIH Grant: 5T32NS007491-13
PI: Bjorn C. Knollman, Ph.D.
Appointment Effective: July 1st, 2013 – June 30th, 2015

SCIENTIFIC SOCIETY MEMBERSHIPS

National Neurotrauma Society (NNS)	2020 - Present
Psychoneuroimmunology Research Society	2017 - 2019
International Society for Serotonin Research	2015 - Present
Phi Lambda Sigma Pharmacy Leadership Society - Alpha Eta Chapter	2013 - Present
Rho Chi Pharmacy Honor Society - Alpha Mu Chapter	2012 - Present
Society for Neuroscience (SfN)	2011 - 2020
American Society for Pharmacology and Experimental Therapeutics (ASPET)	2010 - Present
International Drug Abuse Research Society (IDARS)	2010 - 2018
American Association of Pharmaceutical Scientists (AAPS)	2009 - Present
American Chemical Society (ACS)	2004 - 2007

AWARDS

Excellence in Undergraduate Research Mentoring Award (Nomination) University of Cincinnati	2022
Excellence in Undergraduate Research Mentoring Award University of Cincinnati	2021
Scholarly Excellence Award University of Cincinnati James L. Winkle College of Pharmacy	2019
Mentor Recognition Award University of Cincinnati ASPET SURF Pharmacology Program	2019
Scholarly Excellence Award University of Cincinnati James L. Winkle College of Pharmacy	2018
Mentor Recognition Award University of Cincinnati ASPET SURF Pharmacology Program	2018
ASPET Postdoc Travel Award and Best Abstract Competition – 3rd Place Neuropharmacology Section Experimental Biology – Chicago, IL	2017
ISSR 2016 Postdoctoral Poster Competition – 2nd Place International Society for Serotonin Research Meeting – Seattle, WA	2016
NIDA Travel Award International Society for Serotonin Research Meeting – Seattle, WA	2016
ASPET Postdoc Travel Award and Best Abstract Competition – 1st Place Neuropharmacology Section Experimental Biology – San Diego, CA	2016
Kennedy Center Postdoctoral Travel Award Vanderbilt University – Nashville, TN	2014 – 2015
ASPIRE Federal STEM Policy Externship Funded by NIH Grant: OD018423 PI: Roger G. Chalkley Vanderbilt University – Washington, DC	2014
James A. Bain Young Scientist Travel Award American Society for Pharmacology and Experimental Therapeutics	2014

17 th World Congress of Basic and Clinical Pharmacology – Cape Town, South Africa	
Early Career Science Policy Fellowship	2014
Society for Neuroscience	
Graduate Student Research Award	2013
West Virginia University- School of Pharmacy	
ASPET Graduate Student Best Abstract Competition Finalist	2013
Neuropharmacology Section	
Experimental Biology – Boston, MA	
ASPET Washington Fellows Fellowship Recipient	2012 - 2013
American Society for Pharmacology and Experimental Therapeutics	
Outstanding Achievement Award	2012
West Virginia University - School of Pharmacy	
AAPS Regional Symposium Poster Competition – 1st Place	2011
American Association of Pharmaceutical Scientists	
Duquesne University – Pittsburgh, PA	
STaR Symposium Student Abstract (1 of 10 selected from 560 submissions)	2010
Marshall University – Huntington, WV	
American College of Clinical Pharmacology - Student/Trainee Award	2010
39 th Annual Meeting - Baltimore, MD	
Valuable Contributions Award	2009 - 2011
West Virginia University School of Pharmacy	
BBS Training Scholarship	2009 - 2010
West Virginia University School of Medicine	

PROFESSIONAL SERVICE

Ad Hoc Manuscript Reviewer – Frontiers in Molecular Neuroscience	2022
Ad Hoc Manuscript Reviewer – Toxicology and Applied Pharmacology	2022
IACUC -Alternate Member	2022 - Present
University of Cincinnati	
Review Editor – Frontiers in Stroke	2022 – Present
Population Health and Risk Factors of Stroke Section	
Ad Hoc Manuscript Reviewer – ACS Chemical Neuroscience	2022
Editorial Board Member – Cells	2021 – Present
Veteran’s Affairs – Cincinnati – IACUC Committee – Standing Member	2021 - Present
Associate Editor – Frontiers in Behavioral Neuroscience	2021 - Present
URC Graduate Stipend and Faculty Research Costs Support Program – Chair	2021 - Present
University of Cincinnati Office of Research	
Ad Hoc Manuscript Reviewer – Journal of Pharmacy Practice	2020
Ad Hoc Manuscript Reviewer – Journal of American College of Clinical Pharmacy	2020
Ad Hoc Manuscript Reviewer – Brain Research Bulletin	2020
Ad Hoc Manuscript Reviewer – Brain Sciences	2017 - 2020
Ad Hoc Manuscript Reviewer – Journal of the Neurological Sciences	2020
Ad Hoc Manuscript Reviewer – Theranostics	2020
Ad Hoc Manuscript Reviewer – Biomolecules	2020
Ad Hoc Manuscript Reviewer – Journal of Integrative Neuroscience	2019
Ad Hoc Manuscript Reviewer - Frontiers in Neurology	2019
Research Committee – Standing Member	2019 - Present
University of Cincinnati James L. Winkle College of Pharmacy	
University Research Council – Life Sciences Member	2019 – Present
University of Cincinnati	
Faculty Development Committee – Standing Member	2019 – 2021

University of Cincinnati James L. Winkle College of Pharmacy Committee on Committees – Standing Member	2019 – Present
University of Cincinnati Faculty Senate Ad Hoc Manuscript Reviewer - Cells	2019 - Present
Pharmacy Practice Search Committee Member – Psychiatry	2019
University of Cincinnati James L. Winkle College of Pharmacy Ad Hoc Manuscript Reviewer – Frontiers in Immunology	2018
Admissions Committee - Member	2018 - Present
University of Cincinnati James L. Winkle College of Pharmacy University of Cincinnati – Faculty Senate	2018 - Present
Editorial Board Member – Frontiers in Behavioral Neuroscience	2018 - Present
Ad Hoc Manuscript Reviewer – Molecules	2018
Ad Hoc Manuscript Reviewer – International Journal of Molecular Sciences	2017
Registered Lobbyist – State of Florida	2017
FAU Governmental Affairs Capitol Hill Day	2017
FAU Brain Institute Representative - Tallahassee, FL Ad Hoc Manuscript Reviewer – Genes, Brain & Behavior	2016
Neuropharmacology Executive Committee – Postdoctoral Member	2016 - 2017
American Society for Pharmacology and Experimental Therapeutics Ad Hoc Manuscript Reviewer – Journal of Neuropharmacology	2015
“Hot Topic” Abstract Reviewer – Experimental Biology 2015	2015
American Society for Pharmacology and Experimental Therapeutics Graduate Student Organization - Vice President	2012 - 2013
West Virginia University Drug Discovery Seminar Series Coordinator	2011 - 2013
West Virginia University School of Pharmacy Graduate Student Organization - Member	2011 - 2013
West Virginia University Student Representative - Laboratory Manager Search Committee	2011 - 2012
West Virginia University Chair - American Association of Pharmaceutical Scientists	2011 - 2012
West Virginia University Student Chapter Undergraduate Honors Thesis Committee Member	2010 - 2011
Colleen Beatty – West Virginia University Event Coordinator - Annual School of Pharmacy Research Day	2010 - 2011
West Virginia University School of Pharmacy Chair-Elect - American Association of Pharmaceutical Scientists	2010 - 2011
West Virginia University Student Chapter Community Outreach Program - Student Volunteer	2009 - 2010
West Virginia University School of Pharmacy	

POSTDOCTORAL FELLOWS

Sean Collins – University of Cincinnati – Division of Pharmaceutical Sciences 2018 – 2020

GRADUATE STUDENTS

Christopher O’Connell – Pharmaceutical Sciences 2020 – Present
University of Cincinnati James L. Winkle College of Pharmacy
Evan Reeder – Pharmaceutical Sciences 2018 – Present
University of Cincinnati James L. Winkle College of Pharmacy

MS STUDENTS

Kyla Chilton – Pharmacology and Systems Physiology	2021 – Present
Roman Caseres – Pharmacology and Systems Physiology	2020 – 2021
University of Cincinnati College of Medicine	
Alexandra Dailey – Pharmacology and Systems Physiology	2019 – 2020
University of Cincinnati College of Medicine	
Adam Rowaily – Pharmacology and Systems Physiology	2019 – 2020
University of Cincinnati College of Medicine	
Amber Hussain – Pharmacology and Systems Physiology	2018 – 2019
University of Cincinnati College of Medicine	
Matthew Horchar – Pharmacology and Systems Physiology	2018 – 2019
University of Cincinnati College of Medicine	

UNDERGRADUATE MENTEES

Owen Traubert – University of Cincinnati	2020 - Present
Mei-Ling Liber – University of Cincinnati	2020 - 2021
Savannah Savage – University of Cincinnati	2020 - 2021
Claire Keum – University of Cincinnati	2019 - 2020
Anna (Avery) Benton – Smith College (ASPET SURF Program)	2019
Zachary Smith – University of Cincinnati	2019 - 2020
Sophia Norman – University of Cincinnati (UC Office of Research Undergrad Scholar)	2018 - 2021
Kainat Lungani – University of Cincinnati (Neuro SURF Program)	2018 - 2019
Poornima Gopalan – University of Cincinnati (WISE and Neuro SURF Program)	2018 - 2020
Amelia Long – University of Massachusetts Lowell (ASPET SURF Program)	2018
Jason Thome – University of Cincinnati	2018
Jason Baluja – Florida Atlantic University	2017
Catherine Nettesheim – Florida Atlantic University	2016 - 2017
Jason Thome – Vanderbilt University	2015 - 2016
David A. Botschner – Vanderbilt University	2014 - 2015
Robert Bruner – SURF Student – Emory University	2014
Alexie A. Poch – Vanderbilt University	2013 - 2014
Anna Scandinaro – West Virginia University	2012 - 2013
Colleen Beatty – West Virginia University	2011 - 2012

TEACHING EXPERIENCE

Academic Survival Skills/Success (NS7077)	2022
University of Cincinnati College of Medicine (Course Coordinator)	
Careers in Pharmacogenomics (PHGX9090)	2022
University of Cincinnati James L. Winkle College of Pharmacy	
Therapeutics IV (25PHTH9020)	2020 - Present
University of Cincinnati James L. Winkle College of Pharmacy	
Principles of Pharmaceutical Science Research (PHID8010)	2020 - Present
Metabolism, Molecular Biology & Pharmacogenomics (25PSCI7103)	2019 - Present
University of Cincinnati James L. Winkle College of Pharmacy	
Metabolism, Molecular Biology & Pharmacogenomics (25PSCI7103) – Remediation	2019 - Present
University of Cincinnati James L. Winkle College of Pharmacy	
Mechanisms and Pathologies of Memory and Learning (MEDS4026)	2019 - Present
University of Cincinnati College of Medicine	
Principles of Pharmacology	2018

University of Cincinnati James L. Winkle College of Pharmacy Therapeutics I	2018
University of Cincinnati James L. Winkle College of Pharmacy Pharmaceutical Care Lab II (PHAR712)	2013
West Virginia University School of Pharmacy Immunology/Biotechnology (PHAR709)	2013
West Virginia University School of Pharmacy Pharmaceutical Care Lab I (PHAR701)	2012
West Virginia University School of Pharmacy	

INVITED PRESENTATIONS

High Five: Dissecting Alterations in 5-HT Neurotransmission Following Traumatic Brain Injury Kent State University Brain Health Research Institute Seminar Series – 2/21/2023	2023
Dazed and Confused: Alterations in 5-HT Signaling Following Blast-Induced Traumatic Brain Injury University of Cincinnati Neuroscience Seminar Series	2022
Advocating for Science: Science Policy Careers University of Cincinnati Neuroscience Retreat Panelist	2022
Chronic Traumatic Encephalopathy (CTE): Past Injuries, Present Problems and Future Directions Invited Guest Lecture Graduate Education in Medical Sciences: Introduction to Human Biology and Medicine University of California at San Francisco	2022
Carbon Dioxide Inhalation Mitigates Acute Functional Deficits and Alterations in Hippocampal Gene Transcription Elicited by Blast-Induced Traumatic Brain Injury Invited Presentation Symposium – MHSRS TBI Future Care Today Military Health System Research Symposium 2021 *Cancelled due to COVID-19	2021
One-Two Punch: Impact of 5-HT and 5-HT_{2A} Receptors in Neurotrauma Guest Seminar – McMurray Laboratory Miami University – Department of Psychology	2021
Advocating for Science: Learning How Small Victories Impart Large Change Guest Seminar – Science Policy Ambassadors - Union of Concerned Scientists University of Cincinnati	2021
BLASTed 5-HT: Altered 5-HT Receptor Function and SERT Uptake Following TBI Invited Presentation and Symposium Chair Symposium - One-two punch: Impact of 5-HT and 5-HT _{2A} receptors in neurotrauma International Society for Serotonin Research – 2020 Meeting	2020

*Cancelled due to COVID-19

- Impact of 5-HT Signaling in Traumatic Brain Injury** 2019
Guest Seminar – Canisius College Department of Biochemistry
- Role of Interleukin-1 and Serotonergic Signaling in Blast-Induced TBI** 2018
Collaborative for Research on Acute Neurological Injuries – University of Cincinnati
- p38 MAPK Sustains SERT Ala56-Mediated Serotonergic System Alterations and Social Behavior Perturbations** 2017
Psychoneuroimmunology Research Society – Trainee Data Blitz Session
- Pharmacologic Inhibition and Genetic Elimination of p38 α MAPK Normalizes Serotonergic System Alterations and Social Behavior Deficits in the SERT Ala56 Mouse Model of Autism Spectrum Disorder** 2017
Experimental Biology - Division for Neuropharmacology
- p38 α MAPK: The Missing Puzzle Piece in the Treatment of Autism Spectrum Disorder** 2016
Center for Molecular Biology and Biotechnology Seminar Series
Florida Atlantic University
- Chronic Inhibition of p38 α MAPK Normalizes Serotonin Clearance, Serotonin Receptor Hypersensitivity and Social Behavior Deficits in the SERT Ala56 Genetic Mouse Model of Autism Spectrum Disorder** 2016
International Society for Serotonin Research Meeting –
“The Highs and Lows of Serotonin in Autism Spectrum Disorders” Symposium
- Chronic Antagonism of p38 α MAPK Normalizes Serotonin Clearance, Serotonin Receptor Hypersensitivity and Social Behavior Deficits in a Genetic Murine Model of Autism Spectrum Disorder** 2016
Experimental Biology – Julius Axelrod Symposium
- p38 α MAPK Signaling: Novel Therapeutic Target for the Treatment of Autism Spectrum Disorder?** 2015
Vanderbilt Pharmacology Seminar Series
- Antagonism of p38 α MAPK Reverses ASD-like Phenotypes in the SERT Ala56 Mouse - Vanderbilt NPISA Seminar Series** 2015
- Sigma Receptors as Targets for the Treatment of METH-Induced Neurotoxicity** 2012
West Virginia University School of Pharmacy
- Sigma Receptors: Potential Targets for the Treatment of Psychostimulant Abuse** 2011
Chestnut Ridge Drug Abuse Grand Rounds

PUBLISHED MEDIA ARTICLES

- Robson MJ.** 2013. ‘Sustain investment in biomedical research’ The Dominion Post, Morgantown, WV. 16 June. p. 2D
- Robson MJ.** 2013. ‘Sustain the investment: America’s biomedical research needs to go on for the sake of everyone.’ Finger Lakes Times, Geneva, NY. 7 July. p. 1-2D

Robson MJ. 2014. 'Invest in NIH research.' The Tennessean, Nashville, TN. 5 July.
<http://www.tennessean.com/story/opinion/2014/07/05/invest-nih-research/12223207/>

VOLUNTEER/COMMUNITY SERVICE ACTIVITIES

Assistant Lacrosse Coach Sycamore Girls Lacrosse Program – K - 2	2022
Team Leader/Organizer – “Neurosquad” Palm Beach County Autism Speaks Walk – West Palm Beach, FL	2017
Science Lecture Invitee – Methamphetamine, Cocaine and Your Brain Room in the Inn, Community Center - Nashville, TN	2015
Intensive Outpatient Program - Drug Abuse Research Expert Chestnut Ridge Psychiatric Center - Morgantown, WV	2011
Alternative Spring Break Leader (Canisius College) Habitat for Humanity Volunteer Trip - Cherry Grove, WV	2007
Alternative Spring Break Volunteer (Canisius College) Habitat for Humanity Volunteer Trip - Cherry Grove, WV	2006